Head to Head Survey: Vireo Growth (VREOD) and Its Rivals

Vireo Growth (OTCMKTS:VREOD) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Vireo Growth to similar businesses based on the strength of its analyst recommendations, profitability, institutional ownership, earnings, valuation, dividends and risk.

Profitability

This table compares Vireo Growth and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vireo Growth	-23.37%	-19.76%	-7.15%
Vireo Growth Competitors	-2,393.19%	-220.45%	-16.12%

Risk & Volatility

Vireo Growth has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, Vireo Growth’s competitors have a beta of -0.05, meaning that their average share price is 105% less volatile than the S&P 500.

Insider & Institutional Ownership

32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.8% of Vireo Growth shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Vireo Growth and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vireo Growth	$268.77 million	-$68.11 million	-3.02
Vireo Growth Competitors	$3.54 billion	$3.17 billion	553.75

Vireo Growth’s competitors have higher revenue and earnings than Vireo Growth. Vireo Growth is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Vireo Growth and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vireo Growth	1	0	0	0	1.00
Vireo Growth Competitors	7820	13783	25793	1036	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.81%. Given Vireo Growth’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Vireo Growth has less favorable growth aspects than its competitors.

Summary

Vireo Growth competitors beat Vireo Growth on 9 of the 13 factors compared.

About Vireo Growth

Vireo Growth is a U.S. cannabis company that cultivates, processes and sells cannabis products through licensed operations and retail dispensaries. Its products include cannabis flower and other consumer cannabis offerings, with availability and product types varying by state. The company was formerly known as Goodness Growth Holdings and has roots in Vireo Health, a medical cannabis business. It serves multiple U.S. markets, including Minnesota and New York, as well as other states where it holds licensed operations.